Recent Press Releases

Medigene Starts Phase I/II Study with DC Vaccine to Treat Acute Myeloid Leukaemia (AML)

Martinsried/Munich, 24 March 2015. Biotechnology company Medigene AG (MDG1, Frankfurt, Prime Standard) announces that the company's phase I/II clinical trial with its dendritic cell (DC) vaccine...

Immunovaccine Initiates Phase 2 Clinical Trial of DPX-Survivac Immunotherapy in Recurrent Lymphoma

Trial to Test Efficacy in Diffuse Large B cell Lymphoma Patients with Measurable Disease HALIFAX, NOVA SCOTIA, Mar 24, 2015 (Marketwired via COMTEX) -- Immunovaccine Inc....

GeoVax Appoints Industry Veteran to Its Board of Directors

Randal D. Chase, Ph.D. Brings Extensive Vaccine Background to GeoVax March 23, 2015: 09:00 AM ET GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines...

Sanofi Pasteur Announces FDA Approval of Quadracel DTaP-IPV Combination Vaccine for Children Aged 4-6

Approval allows children to receive a combination of two recommended vaccinations SWIFTWATER, Pa., March 25, 2015 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and...

Sipuleucel-T in prostate cancer: indication of added benefit

Data and analyses subsequently submitted by the drug manufacturer provided better evidence on mortality Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with...

Inovio Pharmaceuticals and Academic Collaborators Receive $16 Million HIV Grant From National Institute of Allergy and Infectious Diseases

PLYMOUTH MEETING, Pa., March 16, 2015 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (Nasdaq:INO) announced today that the company and its academic collaborators, including the University of...

Immunovaccine Announces Intent to Trade on OTCQX Marketplace in United States

Retains PCG Advisory to Build Wall Street Awareness HALIFAX, NOVA SCOTIA, Mar 16, 2015 (Marketwired via COMTEX) -- Immunovaccine Inc. ("Immunovaccine" or "IMV") (IMV), a...

Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company") Proposed Placing and Notice of General Meeting

Placing to raise net proceeds of approximately £20 million to be used to fund the clinical development of Pollinexâ Quattro Grass through to FDA regulatory approval Allergy...

Emergent BioSolutions Signs Agreements With Oxford University, GlaxoSmithKline, and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate

Emergent has completed proof-of concept manufacturing of an MVA Ebola Zaire vaccine candidate anticipated for use in a Phase 1 clinical study in the UK 200L scale production leverages...

Shantha will provide up to 37 million doses of Shan5(TM)

- Shan5(TM) pentavalent pediatric vaccine will protect children against 5 pediatric diseases - Lyon, France - March 17, 2015 - Sanofi Pasteur, the vaccines division of Sanofi, announced today that...

The diabetes vaccine Diamyd® in new study to stop type 1 diabetes in children

Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) informs that DiAPREV-IT 2 has started. In this new study, the second of its kind, the diabetes vaccine Diamyd® is tested to prevent...

Declining Ebola Cases Pose Serious Challenge to Clinical Studies, says GlobalData Analyst

Ebola's dwindling incidence rate directly impacting on patient enrollment for clinical trials Vaccine and drug developers will need to weigh risks and benefits of developing further...

Novavax Appoints Brian Rosen as Vice President, Government Affairs

(Thomson Reuters ONE via COMTEX) -- GAITHERSBURG, Md., March 10, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. NVAX, -0.06% a clinical-stage vaccine company focused on the discovery, development and...

Targovax to expand on-going phase I/II clinical study CT-TG01-01 with a new group of up to 13 patients.

Oslo, March 9, 2015 Press release no 4 - 2015 Immunotherapy specialist Targovax's lead candidate TG01, a novel peptide vaccine against cancer specific RAS mutations, is currently being...

BAVARIAN NORDIC ANNOUNCES 2014 FULL YEAR RESULTS

KVISTGAARD, Denmark, March 11, 2015 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today published its 2014 annual report. Revenue was DKK 1,217 million / USD 175 million (DKK 1,213 million /...

Takeda Announces Transfer of License Agreement for Human Papillomavirus (HPV) Vaccine to Kaketsuke

OSAKA, Japan I March 10, 2015 I Takeda Pharmaceutical Company Limited ("Takeda") today announced that it has transferred its license agreement with the Japan Health Sciences Foundation...

Prime Minister of India launches Made in India ROTAVAC®Vaccine for the world

Hyderabad, Andhra Pradesh, March 9, 2015 /India PRwire/ -- New Delhi/Hyderabad, India, March 9th2015: Hyderabadbased Bharat Biotech announced today the commercial roll out of the Made in India...

Bristol-Myers Squibb Signs Exclusive Agreement with Bavarian Nordic for PROSTVAC®, a Prostate-Specific Antigen-Targeting Cancer Immunotherapy

Bristol-Myers Squibb Signs Exclusive Agreement with Bavarian Nordic for PROSTVAC®, a Prostate-Specific Antigen-Targeting Cancer Immunotherapy Bavarian Nordic to receive up to $975 million,...

Pfizer Receives European Approval for New Indication for Prevenar 13 for Prevention of Vaccine-Type Pneumococcal Pneumonia in Adults

Label Also Updated to Include Data From the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) Tuesday, March 3, 2015 - 8:35am EST Pfizer Inc. (NYSE:PFE) announced...

Targovax appoints Øystein Soug as new CFO

OSLO, Norway--(BUSINESS WIRE)--Targovax is pleased to announce Mr. Øystein Soug as the new CFO of the Company from June 1, 2015 Mr. Øystein Soug, has been the CFO of the late-stage...